Picture of Canbridge Pharmaceuticals logo

1228 Canbridge Pharmaceuticals Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-17.37%
3m-18.4%
6m-44.67%
1yrn/a
Volume Change (%)
10d/3m-84.33%
Price vs... (%)
52w High-67.47%
50d MA-13.69%
200d MA-40.42%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-151.95%
Return on Equityn/a
Operating Margin-3446.38%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Canbridge Pharmaceuticals EPS forecast chart

Profile Summary

Cambridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

Directors

Last Annual
December 31st, 2021
Last Interim
December 31st, 2021
Incorporated
September 1st, 2017
Public Since
December 10th, 2021
No. of Employees
183
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
hk flag iconStock Exchange of Hong Kong Limited
Shares in Issue
424,191,920

1228 Share Price Performance

Upcoming Events for 1228

Similar to 1228

Picture of 3SBio logo

3SBio

hk flag iconStock Exchange of Hong Kong Limited

Picture of Ascletis Pharma logo

Ascletis Pharma

hk flag iconStock Exchange of Hong Kong Limited

Picture of Asymchem Laboratories Tianjin Co logo

Asymchem Laboratories Tianjin Co

hk flag iconStock Exchange of Hong Kong Limited

Picture of Guangzhou Baiyunshan Pharmaceutical Holdings Co logo

Guangzhou Baiyunshan Pharmaceutical Holdings Co

hk flag iconStock Exchange of Hong Kong Limited

Picture of Cansino Biologics logo

Cansino Biologics

hk flag iconStock Exchange of Hong Kong Limited

FAQ

Or unlock with your email

Or unlock with your email